Synthetic Ligand Technology
Purification designed around the molecule
Our synthetic peptide ligands give us precise control over affinity, selectivity, stability, and elution conditions that traditional protein-based ligands simply cannot match.
Optimized Affinity by Design
Synthetic peptide ligands can be developed around the molecular features of a target or impurity. This supports more selective capture or impurity removal where broad binding alone is not enough.
Defined Ligand Chemistry
Synthetic peptide ligands are chemically produced with a defined molecular identity. This supports reproducible ligand manufacture and controlled material specifications.
Fit-for-Purpose Matrix Design
Ligands can be paired with resin or membrane architectures selected around molecule size, pore access, mass transfer and operating conditions. The result is a purification material designed for the process, not just the interaction.
Molecule-Specific Release Behaviour
Binding strength and release conditions can be considered together during development. This creates the potential for milder or more practical product release where supported by application data.
Game-changing breakthroughs for advanced modalities.
Universal binding. Mild elution pH. Higher functional recovery.
A purpose-designed affinity chromatography resin to overcome downstream processing bottlenecks in adeno-associated virus purification.
Move beyond non-selective impurity clearance.
Introducing our targeted HCP removal approach for viral vector processes. Improve downstream robustness without compromising yield.
ChromaGenix experts identify your key impurity bottlenecks and define the requirements for more effective impurity clearance.
Control complex impurity profiles without compromising recovery, product quality or process robustness.
ChromaGenix goes beyond bulk impurity reduction by targeting persistent and high-risk HCP subsets while preserving product recovery and ease of fit into established downstream workflows.
Our experts identify your key impurity bottlenecks and define the requirements for more effective impurity clearance.
Preserve functional vector while simplifying purification.
Our pseudotype-aware affinity approach is being developed to improve lentiviral vector recovery, impurity clearance and process consistency while reducing the need for repeated purification redevelopment across evolving LVV pipelines.
NAVIGATE is currently open to LVV process teams globally, providing early access to emerging technology, expertise and insight to shape the next-generation of LVV purification media.
Resolve dsRNA at the affinity capture step | reduce downstream polishing burden.
Double-stranded RNA is one of the most consequential impurities that can persist through conventional Oligo-dT capture. This introduces downstream burden, added polishing complexity, and immunogenicity risk.
ChromaGenix technology separates dsRNA and mRNA as distinct chromatographic species at the capture step, reducing dsRNA to near-LOQ levels across multiple mRNA constructs in development testing.
Read the full design rationale and data
A practical framework for designing purification around the molecule, the impurity profile and the process constraint — grounded in data and extended across five modalities.
- Why high-titer and advanced-modality processes are straining downstream workflows.
- The AvXcel™ mechanism in full: conserved capsid-junction targeting, multisite avidity, near-neutral elution and the complete specification set.
- How the same logic extends to mRNA, lentiviral, viral vector HCP and recombinant protein HCP — each with its own evidence standard.
- What a credible manufacturing-readiness package looks like: identity, leakage, comparability, cleaning and reuse.